Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBW 2992 (Afatinib) + Docetaxel in Advanced Solid Tumors
NCT02171741Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of afatinib in solid tumor, breast cancer, prostate cancer (PCa) and 1 more, sponsored by Boehringer Ingelheim. Primary endpoints: Incidence and intensity of Adverse Events up to 32 months and Maximum tolerated dose of BIBW 2992 up to 126 days. Started Apr 2005; status: completed.
02
Drugs
afatinib
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02171741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171741.